Journal
CHEMISTRY & BIODIVERSITY
Volume 16, Issue 4, Pages -Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cbdv.201800502
Keywords
histone deacetylase (HDAC) inhibitors; hydroxamic acids; quinazolin-4(3H)-one; molecular docking; cytotoxicity; biological activity
Funding
- National Foundation forScience and Technology of Vietnam (NAFOSTD) [104.01-2016.12]
- Korean Government (NRF) [2017R1A5A2015541]
Ask authors/readers for more resources
The present article describes the synthesis and biological activity of various series of novel hydroxamic acids incorporating quinazolin-4(3H)-ones as novel small molecules targeting histone deacetylases. Biological evaluation showed that these hydroxamic acids were potently cytotoxic against three human cancer cell lines (SW620, colon; PC-3, prostate; NCI-H23, lung). Most compounds displayed superior cytotoxicity than SAHA (suberoylanilide hydroxamic acid, Vorinostat) in term of cytotoxicity. Especially, N-hydroxy-7-(7-methyl-4-oxoquinazolin-3(4H)-yl)heptanamide (5b) and N-hydroxy-7-(6-methyl-4-oxoquinazolin-3(4H)-yl)heptanamide (5c) (IC50 values, 0.10-0.16m) were found to be approximately 30-fold more cytotoxic than SAHA (IC50 values of 3.29-3.67m). N-Hydroxy-7-(4-oxoquinazolin-3(4H)-yl)heptanamide (5a; IC50 values of 0.21-0.38m) was approximately 10- to 15-fold more potent than SAHA in cytotoxicity assay. These compounds also showed comparable HDAC inhibition potency with IC50 values in sub-micromolar ranges. Molecular docking experiments indicated that most compounds, as represented by 5b and 5c, strictly bound to HDAC2 at the active binding site with binding affinities much higher than that of SAHA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available